PYRAZOLOPYRIMIDINE COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONISTS Russian patent published in 2023 - IPC C07D487/04 A61K31/505 A61P35/00 

FIELD: pharmaceutical industry.

SUBSTANCE: compound of Formula (I) or a pharmaceutically acceptable salt thereof, where R¹ represents an optionally substituted phenyl or an optionally substituted 5- or 6-membered aromatic heterocycle containing 1, 2 or 3 heteroatoms independently selected from the group consisting of N, S and O, wherein this phenyl is optionally substituted with 1, 2 or 3 substituents, and each substituent is independently selected from the group consisting of halogen, OH, C_1-8 alkyl, C_1-8 alkyl substituted with 1, 2 or 3 halogens or OH, OC_1-8 alkyl and OC_1-8 alkyl groups substituted with 1, 2 or 3 halogens or OH groups, and wherein this 5- or 6-membered aromatic heterocycle is optionally substituted with 1, 2 or 3 substituents, and each substituent is independently selected from the group consisting of halogen, OH, C_1-8 alkyl, C_1-8 alkyl substituted with 1, 2 or 3 halogens or OH groups, OC_1-8 alkyl and OC_1-8 alkyl substituted with 1, 2 or 3 halogens or OH groups; and R² is an optionally substituted 5- or 6-membered aromatic heterocycle containing 2 or 3 heteroatoms independently selected from the group consisting of N, S, and O, said 5- or 6-membered aromatic heterocycle being optionally substituted with 1, 2 or 3 substituents, and each substituent is independently selected from the group consisting of C_1-3 alkyl and C_1-3 alkyl substituted with 1, 2 or 3 halogens.

EFFECT: proposed pharmaceutical composition contains a compound of Formula (I), the use of compounds of Formula (I) for the production of a drug for the treatment or prevention of a disease or disorder associated with adenosine receptor 2a, and a method for treating or preventing a disease or disorder associated with adenosine receptor 2a.

21 cl, 2 dwg, 3 tbl, 46 ex